EUVIMEDEUVIMED entdecken
Crossref

Discovery of Novel and Potent Prolyl Hydroxylase Domain-Containing Protein (PHD) Inhibitors for The Treatment of Anemia

Jianyu Xu, Xiaoyu Ding, Yanyun Fu, Qingyuan Meng, Ling Wang, Man Zhang, Chenxi Xu, Shan Chen, Alex Aliper iD, Feng Ren iD, Alex Zhavoronkov iD, Xiao Ding iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.3c01932 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Jianyu Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Insilico Medicine Shanghai Ltd, Suite 902, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China. Hauptthemen laut MEDLINE: Prolyl-Hydroxylase Inhibitors, Anemia, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stabilization of hypoxia-inducible factor (HIF) by inhibiting prolyl hydroxylase domain enzymes (PHDs) represents a breakthrough in treating anemia associated with chronic kidney disease. Here, we identified a novel scaffold for noncarboxylic PHD inhibitors by utilizing structure-based drug design (SBDD) and generative models. Iterative optimization of potency and solubility resulted in compound 15 which potently inhibits PHD thus stabilizing HIF-α in vitro. X-ray cocrystal structure confirmed the binding model was distinct from previously reported carboxylic acid PHD inhibitors by pushing away the R383 and Y303 residues resulting in a larger inner subpocket. Furthermore, compound 15 demonstrated a favorable in vitro/in vivo absorption, distribution, metabolism, and excretion (ADME) profile, low drug-drug interaction risk, and clean early safety profiling. Functionally, oral administration of compound 15 at 10 mg/kg every day (QD) mitigated anemia in a 5/6 nephrectomy rat disease model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prolyl-Hydroxylase InhibitorsAnemiaRenal Insufficiency, ChronicRatsAnimalsProlyl HydroxylasesAdministration, OralHypoxia-Inducible Factor-Proline DioxygenasesHypoxia-Inducible Factor 1, alpha Subunit

Substanzen

Prolyl HydroxylasesProlyl-Hydroxylase InhibitorsHypoxia-Inducible Factor-Proline DioxygenasesHypoxia-Inducible Factor 1, alpha Subunit

Autor:innen und Institutionen

  • Insilico Medicine Shanghai Ltd, Suite 902, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China.
  • Insilico Medicine AI Limited, Masdar City, Abu Dhabi 145748, United Arab Emirates.

ORCID-Profile: Alex Aliper, Feng Ren, Alex Zhavoronkov, Xiao Ding

Zitieren

APA

Xu, J., Ding, X., Fu, Y., Meng, Q., Wang, L., Zhang, M., Xu, C., Chen, S., Aliper, A., Ren, F., Zhavoronkov, A., & Ding, X. (2024). Discovery of Novel and Potent Prolyl Hydroxylase Domain-Containing Protein (PHD) Inhibitors for The Treatment of Anemia. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01932

Vancouver

Xu J, Ding X, Fu Y, Meng Q, Wang L, Zhang M, et al. Discovery of Novel and Potent Prolyl Hydroxylase Domain-Containing Protein (PHD) Inhibitors for The Treatment of Anemia. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c01932

BibTeX
@article{Xu2024,
  author = {Xu, Jianyu and Ding, Xiaoyu and Fu, Yanyun and Meng, Qingyuan and Wang, Ling and Zhang, Man and Xu, Chenxi and Chen, Shan and Aliper, Alex and Ren, Feng and Zhavoronkov, Alex and Ding, Xiao},
  title = {Discovery of Novel and Potent Prolyl Hydroxylase Domain-Containing Protein (PHD) Inhibitors for The Treatment of Anemia},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.3c01932}
}
Kostenlos starten →